The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer
Yelena Y. Janjigian(Memorial Sloan Kettering Cancer Center), Akihito Kawazoe(National Cancer Center Hospital East), Patricio Yañez(Universidad de La Frontera), Ning Li(Zhengzhou University), Sara Lonardi(Istituto Oncologico Veneto), О. P. Коlesnik, Olga Barajas(Fundación Arturo López Pérez), Yuxian Bai(Harbin Medical University), Lin Shen(Peking University), Yong Tang(Xinjiang Medical University), Lucjan Wyrwicz(The Maria Sklodowska-Curie National Research Institute of Oncology), Jianming Xu(Chinese PLA General Hospital), Kohei Shitara(National Cancer Center Hospital East), Shukui Qin, Eric Van Cutsem(Universitair Ziekenhuis Leuven), Josep Tabernero(Universitat de Vic - Universitat Central de Catalunya), Lie Li(Merck & Co., Inc., Rahway, NJ, USA (United States)), Sukrut Shah(Merck & Co., Inc., Rahway, NJ, USA (United States)), Pooja Bhagia(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hyun Cheol Chung(Yonsei University)
Cited by 682Open Access
Abstract
Related Papers
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al.|American Journal of Clinical Oncology|1982|11.6k